

Modeling disease mutations by gene targeting in one-cell mouse embryos

Melanie Meyer^{a,b,1}, Oskar Ortiz^{a,1}, Martin Hrabé de Angelis^{b,c}, Wolfgang Wurst^{a,b,d,2}, and Ralf Kühn^{a,b,2}

^aInstitute for Developmental Genetics, Helmholtz Center Munich, 85764 Munich, Germany; ^bTechnical University Munich, 80333 Munich, Germany; ^cInstitute of Experimental Genetics, Helmholtz Center Munich, 85764 Munich, Germany; and ^dDeutsches Zentrum für Neurodegenerative Erkrankungen e. V., 80336 Munich, Germany

Edited by Joseph S. Takahashi, Howard Hughes Medical Institute, University of Texas Southwestern Medical Center, Dallas, TX, and approved April 20, 2012 (received for review December 21, 2011)

Gene targeting by zinc-finger nucleases in one-cell embryos provides an expedite mutagenesis approach in mice, rats, and rabbits. This technology has been recently used to create knockout and knockin mutants through the deletion or insertion of nucleotides. Here we apply zinc-finger nucleases in one-cell mouse embryos to generate disease-related mutants harboring single nucleotide or codon replacements. Using a gene-targeting vector or a synthetic oligodesoxynucleotide as template for homologous recombination, we introduced missense and silent mutations into the *Rab38* gene, encoding a small GTPase that regulates intracellular vesicle trafficking. These results demonstrate the feasibility of seamless gene editing in one-cell embryos to create genetic disease models and establish synthetic oligodesoxynucleotides as a simplified mutagenesis tool.

Gene targeting in embryonic stem (ES) cells is routinely applied to modify the mouse genome and established the mouse as the most commonly used genetic animal model (1). Direct genome editing by zinc-finger nucleases (ZFN) in one-cell embryos has been recently established as an alternative mutagenesis approach in mice, rats, rabbits, and zebrafish (2–9). Such nucleases are designed to induce double-strand breaks (DSBs) at preselected genomic target sites (10–13). DSBs targeted to coding exons frequently undergo sequence deletions leading to gene knockout or allow the insertion (knockin) of DNA sequences from gene-targeting vectors via homologous recombination (HR). We and others recently reported the generation of knockout and knockin mutants at the *Rosa26*, *Mdr1a*, *Pxr*, and *IgM* loci by microinjection of ZFNs one-cell embryos of mice, rats, and rabbits (3, 5, 8).

Genetically modified mammals can serve as valuable models of human inherited disorders, but the majority of disease-associated alleles represent single nucleotide replacements that lead to missense, nonsense, or silent mutations (14, 15). The successful use of ZFNs to induce knockout and knockin alleles prompted us to further explore whether disease-related mutants harboring seamless nucleotide replacements can be created as well. Here we apply gene editing in one-cell mouse embryos to introduce nucleotide replacements into the *Rab38* gene.

RAB38 is a member of the RAB small GTPase family that regulates intracellular vesicle trafficking (16, 17). In mice and rats, *Rab38* is expressed in melanocytes, retinal pigment epithelial cells, alveolar pneumocytes, and platelets (17–20). In *chocolate* mutant mice, the *Rab38* gene exhibits a nucleotide replacement within codon 19 (*Rab38^{chit}*) (21). The resulting G19V amino acid substitution impairs the sorting of the tyrosinase-related protein 1 (TYRP1) into melanosomes, leading to impaired pigment production. Homozygous *Rab38^{chit}* mice exhibit a chocolate-like brown coat color, ocular hypopigmentation, and alterations of the lung surfactants and alveolar structure (22–24). In the rat substrains Fawn-hooded and Cinnamon, a point mutation in the Ruby locus, encoding the *Rab38* homolog, causes hypopigmentation, platelet storage pool deficiency, and lung pathology (19, 20, 25). These RAB38 deficient mutants are considered as phenotypic

models of Hermansky-Pudlak syndrome (HPS) in humans, characterized by oculocutaneous albinism (OCA), progressive pulmonary fibrosis, and platelet storage disease (20, 26, 27). HPS defines a group of eight recessive disorders that arise from defects in the biogenesis of lysosome-related organelles, including melanosomes and platelet-dense granules (26, 27). The genes associated with HPS encode components of the biogenesis of lysosome-related organelles (BLOC-1,-2-3) and the AP3 protein complexes that play roles in intracellular protein trafficking and/or organelle distribution. In *Drosophila*, a synthetic lethal interaction between the BLOC-1 binding partner RAB11 and its paralog *lightoid*, the ortholog of mammalian *Rab38/32*, argues for a partially overlapping function of these RAB proteins (28, 29). Therefore, *Rab38* is considered a HPS-related locus, though patients harboring mutations in *Rab38* have not been identified (26, 27).

By employing ZFNs in one-cell embryos, we introduced missense and silent mutations into the first exon of *Rab38* using a gene-targeting vector or a synthetic oligodesoxynucleotide (ODN) as repair templates. These results demonstrate the feasibility of seamless gene editing in one-cell mouse embryos to create genetic disease models and establish synthetic ODNs as a simplified tool for mutagenesis.

Results

Generation of *Rab38* G19V Mutants by ZFN*Rab38* and Gene-Targeting Vector. For HR with the *Rab38* locus, we designed a gene-targeting vector that includes a glycine to valine replacement at codon 19 (G19V) in the first exon, flanked by homology regions of 0.9 kb and 2.8 kb (Fig. 1A). To create the G19V replacement, a T was placed at the second codon position as found in *Rab38^{chit}* (*chocolate*) mutants (21), whereas a silent A replacement was made at the third position as an identifier for our targeted *Rab38^{IDG-Chit}* allele (Fig. 1B). These replacements further generated a SexAI and erased a BsaJI site and enabled us to discriminate the targeted *Rab38^{IDG-Chit}* and the *Rab38⁺* (wild type) allele by restriction analysis. To stimulate HR at the *Rab38* locus, we used a ZFN pair (ZFN^{Rab38}) with a specific cleavage site located 50 bp downstream of codon 19 (Fig. 1A). To avoid the processing of the targeting vector by ZFN^{Rab38}, the vector's ZFN binding sequences were modified by silent nucleotide replacements (Fig. 1D).

The targeting vector was microinjected together with ZFN^{Rab38} mRNAs into (C57BL/6N × FVB)F₁ mouse one-cell

Author contributions: M.H.d.A., W.W., and R.K. designed research; M.M., O.O., and R.K. performed research; M.H.d.A. contributed new reagents/analytic tools; M.M. and R.K. analyzed data; and M.M., O.O., W.W., and R.K. wrote the paper.

The authors declare no conflict of interest.

This article is a PNAS Direct Submission.

¹M.M. and O.O. contributed equally to this work.

²To whom correspondence may be addressed. E-mail: wurst@helmholtz-muenchen.de or ralf.kuehn@helmholtz-muenchen.de.

This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10.1073/pnas.1121203109/-DCSupplemental.




Fig. 1. Generation of *Rab38* G19V mutants by ZFN^{*Rab38*} and gene-targeting vector. (A) The targeting vector is designed for the insertion of a G19V mutation into the first exon of *Rab38*. The structure of the *Rab38*⁺ locus, the targeted *Rab38*^{IDG-Cht} allele, and the location of the ZFN^{*Rab38*} binding sites of the *Rab38* 5' probe and of PCR primers P-for and P-rev are shown. The positions of SexAI (S), BsaJI (B), and ApaI (A) restriction sites and of SexAI restriction fragments are indicated. (B) Comparison of *Rab38* codons 17–20 of the *Rab38* wild type allele, (*Rab38*⁺) the natural *Rab38* chocolate (*Rab38*^{cht}) allele, and the targeting vector (IDG-Cht). Nucleotides and amino acids differing from the wild type sequence are shown in red. The presence of a thymidine at the second position of codon 19 creates a valine codon, erases a BsaJI, and generates a SexAI site. The IDG-Cht G19V replacement was marked with an additional silent replacement at the third position of codon 19. (C) PCR amplification of the first exon of *Rab38* from C57BL/6 (B6), homozygous *Rab38*^{cht} (Cht/Cht), heterozygous *Rab38*^{cht} (Cht/+) control mice and pup R1.1 derived from embryos injected with ZFN^{*Rab38*} and targeting vector (upper image). PCR products were digested with BsaJI (lower image) to determine the *Rab38* genotype of pup R1.1 as *Rab38*⁺/*Rab38*^{IDG-Cht}. (D) Comparison of sequences within the first exon of the *Rab38* wild type gene, the targeting vector (IDG-Cht) and of BsaJI resistant PCR products amplified with primers P-for and P-rev from genomic DNA of pups R1.1, R3.5 and R3.9. The position of codon 19 and the ZFN^{*Rab38*} binding regions are indicated. Nucleotides differing from the wild type sequence (blue background) are shown on a yellow background. (E) Southern blot analysis of SexAI digested genomic DNA using the *Rab38* 5' probe shows a 10.5 kb and a 6.0 kb fragment from the *Rab38*⁺ loci of two C57BL/6 (B6) control mice and an additional 2.1 kb band derived from the targeted *Rab38*^{IDG-Cht} allele of pups R1.1, R3.5, and R3.9. Homozygous *Rab38*^{IDG-Cht} mutants (#47, #86) show the 10.5 kb and 2.1 kb bands, but not the 6.0 kb band. (F) Comparison of the coat color of a wild type C57BL/6N mouse and a homozygous *Rab38*^{IDG-Cht} (#47) mouse.

embryos. From these injections, we obtained 87 offspring that were first genotyped for the presence of the *Rab38*^{IDG-Cht} allele by PCR analysis. For this purpose, a 213 bp region of the first exon of *Rab38* was PCR-amplified from tail DNA and digested with BsaJI. PCR products derived from the *Rab38*⁺ locus of wild type controls can be fully digested with BsaJI into fragments of 153 bp and 60 bp (Fig. 1C, B6). In contrast, the PCR product derived from homozygous *Rab38*^{cht} mice is entirely resistant to BsaJI digestion (Fig. 1C, Cht/Cht), while PCR products from heterozygous mutants are only partially digestible due to the presence of a mutant, BsaJI-resistant allele (Fig. 1C, Cht/+). Among

the 87 offspring from microinjections, we identified three pups (male R1.1, male R3.5, and female R3.9) which showed a partial resistance of PCR products to BsaJI digestion, as predicted for the presence of a *Rab38*^{IDG-Cht} allele (Fig. 1C, R1.1). These *Rab38*^{IDG-Cht} alleles were further characterized by sequence analysis of BsaJI-resistant PCR products derived from the recombinant loci. As shown in Fig. 1D, all three samples exhibit the targeted G19V mutation and the silent exchange at the third position of codon 19 that identifies the targeted mutation. The targeted allele of pups R1.1 and R3.5 further included all silent mutations within the ZFN binding sites, whereas in pup

R3.9 HR was terminated between these regions (Fig. 1D). To confirm the integrity of the targeted alleles, we analyzed genomic DNA derived from the three PCR-positive pups by Southern blotting using a hybridization probe located upstream of the vector's 5'-homology arm (Fig. 1A). Upon digestion with SexAI, the *Rab38^{IDG-Chi}* allele is predicted to generate a 2.1 kb band instead of the 6.0 kb band derived from the wild type locus (Fig. 1A). This analysis showed that the pups R1.1, R3.5, and R3.9 all exhibit the indicative 2.1 kb band which corresponds to a successful HR event of the targeting vector with a *Rab38⁺* allele (Fig. 1E).

Taken together, the PCR and Southern blot analysis confirmed the identity and integrity of the targeted *Rab38^{IDG-Chi}* alleles in the founder mice R1.1, R3.5, and R3.9. These mutants were identified among 87 pups derived from embryo injections, corresponding to a recombination rate of 3.5% at *Rab38*. This efficiency is comparable to our previous results from the *Rosa26* locus that showed a 2%–4% rate for the ZFN-mediated integration of reporter genes (8).

To establish breeding colonies of *Rab38^{IDG-Chi}* mutants, the founders were mated and the resulting offspring were genotyped for the presence of the targeted allele by PCR and Southern blot analysis. Founder R1.1 transmitted the *Rab38^{IDG-Chi}* allele to 8 of 22 pups (36%), founder R3.5 to 5 of 24 pups (21%) and founder R3.9 to 5 of 10 pups (50%) indicating that ZFN^{Rab38} expression did not interfere with the founder's fertility. Statistical analysis revealed that mutant offspring appear at a submendelian ratio (18 positive pups of 56, $P = 0.01045$), suggesting that likely the founder mice R1.1 and R3.5 represent a mosaic of heterozygous targeted and wild type cells. Heterozygous mutant offspring were further mated to generate homozygous *Rab38^{IDG-Chi}* mice. Genotyping of these offspring revealed a genotype distribution of 30.9% homozygote *Rab38^{IDG-Chi}* (Fig. 1E, #47, #86), 48.1% heterozygote *Rab38^{IDG-Chi}*, and 21.0% *Rab38^{+/+}* pups. The homozygous carriers of the *Rab38^{IDG-Chi}* mutation exhibited the expected chocolate-like coat color (Fig. 1F, #47), as known from the natural *Rab38^{cht}* mutants (21). This result indicates the functionality of the G19V mutation of the targeted *Rab38^{IDG-Chi}* allele and provides the first genetic model with a targeted codon replacement generated by ZFN-assisted HR in one-cell embryos.

Targeting of the *Rab38* Gene by ZFN^{Rab38} and a Synthetic Oligodesoxynucleotide. We further explored whether nucleotide replacements can be introduced into the *Rab38* gene by the coinjection of ZFN^{Rab38} and a single-stranded synthetic ODN instead of a plasmid-based gene-targeting vector. For this purpose, we used ODN^{IDG-WT} corresponding to 144 nucleotides of the sense sequence of the first exon of *Rab38* (Fig. 2A). ODN^{IDG-WT} was designed to generate a *Rab38^{IDG-WT}* allele by introduction of a silent nucleotide replacement within codon 18 (Fig. 2B). In addition, the ZFN^{Rab38} recognition sequences were modified by silent replacements to prevent the potential processing of targeted alleles by ZFN nucleases (Fig. 2D). In addition, these replacements remove an ApaLI site from codon 30/31 (Fig. 2B). The ODN^{IDG-WT} was coinjected with ZFN^{Rab38} mRNAs into one-cell embryos derived from FVB female and *Rab38^{cht}* (21) male mice. From these injections we obtained 60 pups that were genotyped for the presence of the *Rab38^{IDG-WT}* allele by PCR amplification of a 213 bp region from the first exon of *Rab38* (Fig. 2A). A fully recombined *Rab38^{IDG-WT}* allele could be distinguished from the *Rab38⁺* and *Rab38^{cht}* alleles by the absence of the ApaLI site in the PCR fragment. PCR products from the *Rab38⁺* and *Rab38^{IDG-WT}* allele can be cleaved with BsaJI into 153 bp and 60 bp fragments (Fig. 2C, samples B6 and C7.4), whereas product from the *Rab38^{cht}* allele is resistant to BsaJI.

Interestingly, the PCR products from pup C7.3 showed partial resistance to ApaLI and BsaJI digestion (Fig. 2C). In contrast, PCR products from Pup C7.4 showed partial resistance to ApaLI but no resistance to BsaJI digestion (Fig. 2C). The sequence

analysis of PCR products from pup C7.3 revealed a recombined *Rab38^{IDG-WT}* allele that includes the nucleotide replacement within codon 18 and the upstream ZFN binding site, but not the replacements in the downstream ZFN binding site and in codon 44 (Fig. 2D). The Southern blot analysis of SexAI-digested DNA from pup C7.3 using the *Rab38* 5'-probe showed the presence of an unmodified *Rab38^{cht}* allele as indicated by a 2.1 kb band (Fig. 2E). The genotype of pup C7.3 was further analyzed by digestion with ApaLI and confirmed the presence of a *Rab38^{IDG-WT}* allele by an indicative 10.5 kb band and of the *Rab38^{cht}* allele by a 6.6 kb band (Fig. 2F). Therefore, pup C7.3 exhibits a *Rab38^{IDG-WT}/Rab38^{cht}* genotype, suggesting that ODN^{IDG-WT} recombined with the maternal *Rab38⁺* allele, whereas the paternal *Rab38^{cht}* allele was unaffected. For the *Rab38^{IDG-WT}* allele HR occurred in the sequence covering codon 18 to 33, but was terminated between the oligonucleotide's silent replacements in the ZFN binding sites (Fig. 2D). Upon mating of the female founder C7.3 to wild type C57Bl/6 males, we obtained 13 pups, 4 of which harbored a *Rab38^{IDG-WT}/Rab38⁺* genotype as determined by PCR and Southern blot analysis (Fig. S1A and B). The sequence analysis of PCR products derived from the germ line transmitted *Rab38^{IDG-WT}* alleles showed their identity to the maternal allele of the founder C7.3 (Fig. S1C).

In contrast, the sequence and Southern blot analysis of DNA from pup C7.4 revealed the absence of a BsaJI-resistant, *Rab38^{cht}* allele and the loss of the ApaLI site through a 27 bp deletion (Δ) within the ZFN^{Rab38} binding site (Fig. 2D–F). This *Rab38⁺/Rab38^Δ* genotype may arise by gene conversion from the maternal *Rab38⁺* to the paternal *Rab38^{cht}* allele, followed by a NHEJ repair-associated deletion that occurred in a second binding cycle of ZFN^{Rab38} to the recombined allele.

Taken together, we obtained from 60 pups derived from microinjections one *Rab38^{IDG-WT}* mutant (1.7%) that transmitted the modified allele to its offspring. This result provides proof-of-principle for the creation of single nucleotide replacements directly in one-cell embryos using ZFN technology and ODNs.

Discussion

ZFN-assisted gene editing in one-cell embryos provides a new, ES cell-independent paradigm to modify the genome of mammals and other vertebrates. The frequent loss of nucleotides associated with the NHEJ-mediated repair of induced DSBs provides an easy route for creating functional knockout alleles in the germline of mice, rats, rabbits, and zebrafish (2–9). The resulting loss-of-function mutants serve as valuable tools to decipher the essential role of targeted genes within the functional network that determines biological processes in vivo. Besides gene knockout, more specific questions on gene function require the creation of precisely targeted mutations, such as the replacement of codons for modeling disease alleles or the insertion of recombinase recognition sites to generate conditional alleles. This targeted mutagenesis approach requires the use of gene-targeting vectors which serve as template for the HR-mediated transfer of preplanned sequence modifications into the genome (1, 30). ZFN-assisted HR has been successfully used in mouse, rat, and rabbit models for the insertion of reporter genes (3, 5, 8), but the replacement of specific codons has yet not been reported.

By microinjection of ZFN^{Rab38} and a gene-targeting vector into one-cell embryos, we were able to introduce a G19V *chocolate* mutation into the mouse *Rab38* gene. Upon transfer of the injected embryos, we obtained three founder mice harboring the targeted mutation. Additional silent replacements, included into the ZFN-binding motifs of the targeting vector to prevent its nuclease processing, were cotransferred into the genome of two founders, but only partly transferred to the third founder. To avoid the cotransfer of such modifications in the future, we propose to include only one nucleotide replacement within the distant ZFN binding region. The three founders (two males,




Fig. 2. Targeting of the *Rab38* gene by ZFN^{Rab38} and a synthetic oligodesoxynucleotide. (A) The targeting oligonucleotide ODN^{IDG-WT} is designed for the introduction of a silent nucleotide replacement in codon 18 of a *Rab38*⁺ or *Rab38*^{cht} allele. The structure of the *Rab38*⁺ and the *Rab38*^{cht} (cht) locus, of the targeted *Rab38*^{IDG-WT} allele, the location of the ZFN^{Rab38} binding sites of the *Rab38* 5'-probe and of PCR primers P-for and P-rev are shown. The positions of SexAI (S), BsaJI (B), and ApaLI (A) restriction sites and of SexAI and ApaLI restriction fragments are indicated. The *Rab38*^{cht} allele (cht) differs from *Rab38*⁺ (+) by the presence of a SexAI site instead of a BsaJI site in the first exon. (B) Comparison of *Rab38* codons 17–19 and 30/31 of the *Rab38* wild type allele (*Rab38*⁺), the *Rab38*^{cht} allele and the targeting ODN^{IDG-WT}. Nucleotides and amino acids differing from the wild type sequence are shown in red. For ODN^{IDG-WT}, the presence of a thymidine at the third position of codon 31 erases an ApaLI site. (C) PCR amplification with primer pair P-for/P-rev of a 213 bp region covering the first exon of *Rab38* from DNA from a C57BL/6 (B6) and a homozygous *Rab38*^{IDG-Cht} (IDG-Cht/IDG-Cht) control mouse and pups C7.3 and C7.4 derived from *Rab38*^{+/Rab38}^{cht} embryos injected with ZFN^{Rab38} and targeting ODN^{IDG-WT}. The *Rab38* genotype was determined by digestion of the PCR products with BsaJI, or ApaLI. PCR products derived from a *Rab38*⁺ allele (B6) or a targeted *Rab38*^{IDG-WT} allele (recombined within codon 18) are digested by BsaJI into fragments of 153 bp and 60 bp; product from *Rab38*^{IDG-Cht} alleles (IDG-Cht/IDG-Cht) is resistant to BsaJI digestion. Digestion with ApaLI of PCR products from *Rab38*⁺ and *Rab38*^{IDG-Cht} alleles results into fragments of 115 bp and 98 bp that appear within a single band; product from a *Rab38*^{IDG-Cht} allele (recombined within codon 30/31) is resistant to ApaLI digestion. The analysis of PCR products showed in both pups C7.3 and C7.4 the presence of an ApaLI resistant *Rab38* allele. The more diffuse appearance of the ApaLI resistant PCR product of sample 7.4 is likely explained by the presence of a 27 bp deletion (see D) resulting in a reduced size of 186 bp and either an incomplete digestion or the presence of hybrid molecules formed with full-length wild type DNA strands. Pup C7.3 but not C7.4 harbors a BsaJI resistant *Rab38*^{cht} allele. M: 100 bp size ladder. (D) Comparison of sequences within the first exon of the *Rab38*⁺ and *Rab38*^{cht} alleles, the targeting ODN^{IDG-WT}, and of ApaLI-resistant PCR products amplified with primers P-for and P-rev from genomic DNA of pups C7.3 and C7.4. The position of codon 18 and the ZFN^{Rab38} binding regions are indicated. Nucleotides differing from the wild type sequence (blue background) are shown on a yellow background; nucleotide deletions are indicated by a dash. (E) Southern blot analysis of SexAI digested genomic DNA using the *Rab38* 5'-probe shows the presence of *Rab38*^{cht} alleles (2.1 kb band) in a homozygous *Rab38*^{IDG-Cht} control mouse (IDG-Cht) and pup C7.3 but its absence in pup C7.4. (F) Southern blot analysis of ApaLI digested genomic DNA using the *Rab38* 5'-probe shows a 6.6 kb fragment from the *Rab38*⁺ alleles of a C57BL/6 control mouse (B6) and a 10.5 kb band for the *Rab38*^{IDG-Cht} alleles from a homozygous *Rab38*^{IDG-Cht} control (IDG-Cht/IDG-Cht). Both pups C7.3 and C7.4 exhibit a 6.6 kb band from an unmodified *Rab38*⁺ (C7.4) or *Rab38*^{cht} (C7.3) allele and a 10.5 kb band derived from an ApaLI resistant *Rab38*^{IDG-WT} allele in pup C7.3 and a *Rab38*⁺ allele in pup C7.4.

one female) transmitted the *Rab38*^{IDG-Cht} allele to 32% of their offspring, indicating that ZFN manipulation does not interfere with fertility and that some of the founders were not fully heterozygous but mosaic for the targeted allele. As we noticed earlier, founders derived from one-cell embryo injections represent

either fully heterozygous mutants that harbor the mutant allele in all body cells or mosaic mutants that bear the mutation in only part of the cells (8). Fully heterozygous founders are obtained if HR occurs in the pronucleus before genome replication, whereas later recombination at only one of the four parental chromatids

results into mosaic heterozygotes. Further breeding of heterozygotes resulted in homozygous *Rab38*^{IDG-Cht} mutants that recapitulated the coat color phenotype of the natural *Rab38*^{cht} mutants.

Here we demonstrate that a mouse mutant harboring a pre-planned codon replacement could be generated in a single step by gene targeting in one-cell embryos. As compared to the genetic manipulation of ES cells, gene targeting in one-cell embryos represents a straightforward approach that directly results in founder animals that can be used to establish a mutant colony. One-cell embryo gene targeting does not require the incorporation of selection marker genes into targeting vectors, which is an essential component of targeting vectors used for ES cell engineering. In addition, mutants established from ES cells require an additional breeding step for removal of the selection marker by Flp recombinase in order to avoid its interference with the function of the targeted gene (31, 32).

Typical gene-targeting vectors are plasmid-based constructs that include 4–10 kb homology regions derived from the target locus to guide the insertion of a desired mutation during the HR process (30). The construction of gene-targeting vectors is commonly a low-throughput and time-consuming task. In addition, the large size of these DNA constructs limits the number of molecules that can be introduced into embryos without eliciting toxicity. Both of these limitations are bypassed by the use of synthetic ODNs as sequence-specific repair templates. As recently shown in cultured cell lines, ZFN-mediated gene targeting is achieved with ODNs at a similar rate as compared to the use of classical targeting vectors (33). Our results with an ODN targeting the *Rab38* gene indicate that these molecules also serve as repair templates in one-cell embryos, enabling nucleotide replacements. This simplified targeting approach expedites the generation of mutant alleles as compared to the time-consuming construction of plasmid vectors. Since ODNs are able to induce in vitro sequence insertions and deletions (33), we expect that such modifications will further expand the utility of ODN-directed gene targeting in embryos. As it was also shown that the inclusion of silent mutations into targeting ODNs is not mandatory (33), we expect that it will be possible to generate targeted alleles without any modification in the ZFN recognition sequence.

Taken together, we demonstrate that mutants harboring nucleotide replacements can be generated by gene editing in one-cell embryos. Furthermore, we show that a synthetic ODN serves as repair template. We consider these techniques useful for the generation of genetic disease models in rodents and other vertebrates to study the role of human disease-associated mutations, which mostly exhibit single nucleotide replacements (14, 15). As recently reported for rats and zebrafish, the limited availability of ZFNs is overcome by the use of modular TAL-based nucleases that enable to address any genomic target site (34, 35). These findings and our results of nucleotide specific gene editing open further prospects for modeling human disease alleles in vertebrates.

Material and Methods

Targeting Vector and Single-Stranded Oligodesoxynucleotide Design. The targeting vector pRab38(IDG-Cht) comprised two homology regions encompassing 942 and 2788 bp of genomic sequence flanking exon 1 of the mouse *Rab38* gene (Fig. 1A). For this purpose, the vector's 5'- and 3'-homology arms were amplified from the genomic BAC clone RPCI-421G2 (derived from the C57BL/6J genome, Imagenes GmbH, Berlin) using the primer pair RabCht-1 (5'-CTCACCGATTACCCCTGGCGTTGAAACCGAAGAAGACC-3') and RabCht-2 (5'-GATAATGCTGGTCTTGCCCACTaCCAGGTCGCCGATC-3'), and the primer pair RabCht-3 (5'-GTGGGCAAGACCAGCATTATCAAGCGCTA-TGTGCAiCAAAiTTCTCTCGACTaTCGaGCCACCATTGGTGTGGACTTCG-3') and RabCht-4 (5'-GCTTATCGA-TACCGTCCGACTCAGTTGACTACTACCCGTTTC-3'). Primers

RabCht-2 and -3 were selected such that they overlap by 21 bp within exon 1 of *Rab38*, immediately downstream of codon 19. Within the sequence of codon 19, primer RabCht-2 contained two nucleotide changes (small letters) that modify codon 19 from the wild type sequence GGT, coding for glycine, into GTA, coding for valine. This new *chocolate* mutation can be distinguished from the natural *chocolate* mutation, which exhibits only a single nucleotide exchange within codon 19 (GTT) coding for valine (21). The recognition region for the ZFN-Rab38-L and -R zinc-finger proteins is located 50 bp downstream of codon 19. For the construction of the targeting vector, each 18 bp ZFN recognition sequence in the 3'-homology region was further modified by the introduction of two silent nucleotide substitutions (small letters) that do not alter the *Rab38* coding sequence (Fig. 1D), in order to avoid the potential processing of the targeting vector by the *Rab38* specific ZFNs. To construct the complete pRab38(IDG-Cht) targeting vector, the PCR products representing the 5'- and 3'- homology arms were combined by fusion PCR using primers RabCht-1 and -4 for amplification. Since primer 1 includes an I-SceI restriction site and primer 4 a SalI restriction site, the I-SceI and SalI digested 3.7 kb PCR product was cloned into the backbone of the vector pRosa26.3-3 (8) that was opened with I-SceI and SalI. The integrity of the completed vector was confirmed by DNA sequencing.

The targeting oligodesoxynucleotide ODN^{IDG-WT} for the second experiment, synthesized by Metabion (Martinsried, Germany), had a total length of 144 nucleotides including the IDG-WT mutation (Fig. 2B), and silent mutations within the ZFN recognition site (Fig. 2D). An additional silent mutation was included in codon 44 to differentiate between the *Rab38*⁺ allele and *Rab38*^{IDG-WT} allele (Fig. 2D).

Injection of One-Cell Embryos. The heterodimeric ZFN^{Rab38} pair targets sequences (underlined) near to the site of the *chocolate* mutation (here WT sequence; bold) within the first exon of the mouse *Rab38* gene: 5'-atgcagaccctcacaaggagcactgtacaagctgctggtgatcgccgactgggtgtgggcaagaccagcattatacaagcgctatgtgacc-aaaactctctcctcgactaccgggcccacattgtgtgactcgcgctgaaggtgctccactgggaccagagacggtggtgctgagctctgggacattgctg-3'. Expression constructs for these ZFNs were generated by gene synthesis (GenScript), followed by embedding of the reported ZFN recognition helix sequences (9) into a generic zinc-finger backbone based on the sequence of the ZIF268 protein (10, 36–38). For the preparation of ZFN^{Rab38} mRNA, in vitro transcription from plasmid DNAs were performed as previously described (8). Each ZFN^{Rab38} mRNA was diluted in injection buffer to a working concentration of 3 ng/μL for the first experiment and a working concentration of 7.5 ng/μL for the second. mRNAs were mixed and stored together with the targeting vector or ODN at –80 °C. The targeting vector pRab38(IDG-Cht) was used as a supercoiled plasmid. The vector was precipitated and dissolved in injection buffer to a working concentration of 15 ng/μL. The targeting oligodesoxynucleotide ODN^{IDG-WT} was dissolved in water and diluted with injection buffer to a working concentration of 15 ng/μL. Mouse zygotes for the first experiment were obtained by mating of C57BL/6N males with superovulated FVB females (Charles River Germany) as described (8). In the second experiment, homozygous *Rab38*^{cht} males (21), kindly provided by M. Seabra, were used instead of C57BL/6N. Zygotes were injected with a mixture of the targeting construct (15 ng/μL) and the ZFN^{Rab38} mRNA (3 ng/μL each or 7.5 ng/μL each) in the same two-step procedure as described (8). Microinjections were performed into the larger (male) pronucleus of fertilized oocytes whenever possible. For those zygotes in which the pronuclei showed no obvious size difference, one of the pronuclei was randomly selected. Injected zygotes were transferred into pseudopregnant CD1 female mice, and viable adult mice were obtained. From the transfer of 428 zygotes, injected with the targeting vector pRab38(IDG-Cht), we obtained 87 newborns

(20% recovery). The animals with correct homologous recombination events were mated, and the offspring were analyzed for germ line transmission. Whether the mutant allele was inherited at mendelian ratio was calculated with the exact binomial test using the R software (39). With the targeting oligodesoxynucleotide ODN^{IDG-WT}, we obtained 60 mice from 180 transferred zygotes (33% recovery). All mice showed normal development and appeared healthy. Mice were handled according to institutional guidelines and housed in standard cages in a specific pathogen-free facility on a 12-h light/dark cycle with ad libitum access to food and water.

Preparation of Genomic DNA. Genomic DNA was isolated from tail tips of mice derived from zygotes coinjected with ZFN^{Rab38} mRNA and pRab38(IDG-Cht) vector or ODN^{IDG-WT}, following the Wizard Genomic DNA Purification Kit (Promega) protocol. The obtained DNA pellet was dissolved in 100 μ L 10 mM Tris-Cl, pH 8.5, incubated overnight at room temperature, and stored for further analysis at 4°C.

PCR, Digestion, and Sequence Analysis. To analyze the *Rab38* alleles in the first round, we amplified the DNA from mice using the PCR primer pair P for (5'-GGCCTCCAGGATGCAGACACC-3') and P_{rev} (5'-CCAGCAATGTCCCAGAGCTGC-3'). Amplification was performed using Taq polymerase (Qiagen) in 25 μ L reactions with 35 cycles of 94°C—40 s, 58°C—40 s, 72°C—1 min. Afterwards, the PCR products were directly

digested with 10 units of restriction enzyme in a volume of 30 μ L and loaded on an 1.5% agarose gel. The undigested fragments, which showed the homologous recombined allele, were extracted with the Qiaquick Gel Extraction Kit (Qiagen, Hilden, Germany) and sent for sequencing (GATC, Konstanz, Germany). The results were compared to the expected sequences using the Vector NTI software (Invitrogen).

Southern Blot Analysis. Genomic DNA from positive recombined mice was digested overnight with the appropriate restriction enzyme. Southern blot analysis was performed as previously described (8), except for the washing step that was performed with 1x SSC at 70°C (2 \times 20 min.) using the *Rab38* 5'-probe, which was obtained by PCR amplification (P-Rab1: 5'-ctggaactaaaatt-caaggtgtatac-3', P-Rab2: 5'-TATTCATCACTTAACCATTTG-TTC-3') from C57BL/6N genomic DNA and purified with the Qiaquick PCR Purification Kit (Qiagen).

ACKNOWLEDGMENTS. We thank R. Kneutinger, P. Kunath, A. Krause, A. Tasdemir, and S. Weidemann for excellent technical assistance; M. Seabra for *Rab38^{cht}* mice; T. Faus-Kessler for statistical analysis; and B. Wefers and A. Pertek for reading the manuscript. This work was supported by the European Union within the EUCOMM project (Grant #LSHG-CT-2005-018931, to W.W.), by the German Ministry of Education and Research within the DIGTOP project (Grant #01GS0858, to W.W. and R.K.) of the NGFN-Plus program, and by the European Union Seventh Framework Programme (Grant #FP7/2007-2013, to O.O.) under grant agreement no. 251864.

1. Capecchi MR (2005) Gene targeting in mice: Functional analysis of the mammalian genome for the twenty-first century. *Nat Rev Genet* 6:507–512.
2. Carbery ID, et al. (2010) Targeted genome modification in mice using zinc-finger nucleases. *Genetics* 186:451–459.
3. Cui X, et al. (2011) Targeted integration in rat and mouse embryos with zinc-finger nucleases. *Nat Biotechnol* 29:64–67.
4. Doyon Y, et al. (2008) Heritable targeted gene disruption in zebrafish using designed zinc-finger nucleases. *Nat Biotechnol* 26:702–708.
5. Flisikowska T, et al. (2011) Efficient immunoglobulin gene disruption and targeted replacement in rabbit using zinc finger nucleases. *PLoS One* 6:e21045.
6. Mashimo T, et al. (2010) Generation of knockout rats with X-linked severe combined immunodeficiency (X-SCID) using zinc-finger nucleases. *PLoS One* 5:e8870.
7. Meng X, Noyes MB, Zhu LJ, Lawson ND, Wolfe SA (2008) Targeted gene inactivation in zebrafish using engineered zinc-finger nucleases. *Nat Biotechnol* 26:695–701.
8. Meyer M, de Angelis MH, Wurst W, Kuhn R (2010) Gene targeting by homologous recombination in mouse zygotes mediated by zinc-finger nucleases. *Proc Natl Acad Sci USA* 107:15022–15026.
9. Geurts AM, et al. (2009) Knockout rats via embryo microinjection of zinc-finger nucleases. *Science* 325:433.
10. Klug A (2010) The discovery of zinc fingers and their development for practical applications in gene regulation and genome manipulation. *Q Rev Biophys* 43:1–21.
11. Porteus MH, Carroll D (2005) Gene targeting using zinc finger nucleases. *Nat Biotechnol* 23:967–973.
12. Porteus MH, Baltimore D (2003) Chimeric nucleases stimulate gene targeting in human cells. *Science* 300:763.
13. Santiago Y, et al. (2008) Targeted gene knockout in mammalian cells by using engineered zinc-finger nucleases. *Proc Natl Acad Sci USA* 105:5809–5814.
14. Sauna ZE, Kimchi-Sarfaty C (2011) Understanding the contribution of synonymous mutations to human disease. *Nat Rev Genet* 12:683–691.
15. Stenson PD, et al. (2009) The Human Gene Mutation Database: 2008 update. *Genome Med* 1:13.
16. Corbeel L, Freson K (2008) Rab proteins and Rab-associated proteins: Major actors in the mechanism of protein-trafficking disorders. *Eur J Pediatr* 167:723–729.
17. Osanai K, et al. (2005) Expression and characterization of Rab38, a new member of the Rab small G protein family. *Biol Chem* 386:143–153.
18. Brooks BP, et al. (2007) Analysis of ocular hypopigmentation in Rab38^{cht/cht} mice. *Invest Ophthalmol Vis Sci* 48:3905–3913.
19. Ninkovic I, White JG, Rangel-Filho A, Datta YH (2008) The role of Rab38 in platelet dense granule defects. *J Thromb Haemost* 6:2143–2151.
20. Osanai K, et al. (2010) Altered lung surfactant system in a Rab38-deficient rat model of Hermansky-Pudlak syndrome. *Am J Physiol Lung Cell Mol Physiol* 298:L243–251.
21. Loftus SK, et al. (2002) Mutation of melanosome protein RAB38 in chocolate mice. *Proc Natl Acad Sci USA* 99:4471–4476.
22. Lopes VS, Wasmeier C, Seabra MC, Futter CE (2007) Melanosome maturation defect in Rab38-deficient retinal pigment epithelium results in instability of immature melanosomes during transient melanogenesis. *Mol Biol Cell* 18:3914–3927.
23. Wasmeier C, et al. (2006) Rab38 and Rab32 control post-Golgi trafficking of melanogenic enzymes. *J Cell Biol* 175:271–281.
24. Osanai K, et al. (2008) A mutation in Rab38 small GTPase causes abnormal lung surfactant homeostasis and aberrant alveolar structure in mice. *Am J Pathol* 173:1265–1274.
25. Oiso N, Riddle SR, Serikawa T, Kuramoto T, Spritz RA (2004) The rat Ruby (R) locus is Rab38: Identical mutations in Fawn-hooded and Tester-Moriyama rats derived from an ancestral Long Evans rat sub-strain. *Mamm Genome* 15:307–314.
26. Di Pietro SM, Dell'Angelica EC (2005) The cell biology of Hermansky-Pudlak syndrome: Recent advances. *Traffic* 6:525–533.
27. Wei ML (2006) Hermansky-Pudlak syndrome: A disease of protein trafficking and organelle function. *Pigment Cell Res* 19:19–42.
28. Ma J, Plesken H, Treisman JE, Edelman-Novemsky I, Ren M (2004) Lightoid and Claret: A rab GTPase and its putative guanine nucleotide exchange factor in biogenesis of Drosophila eye pigment granules. *Proc Natl Acad Sci USA* 101:11652–11657.
29. Rodriguez-Fernandez IA, Dell'Angelica EC (2009) A data-mining approach to rank candidate protein-binding partners-The case of biogenesis of lysosome-related organelles complex-1 (BLOC-1). *J Inherit Metab Dis* 32:190–203.
30. Hasty P, Abuin A, Bradley A (2000) Gene targeting, principles, and practice in mammalian cells. *Gene Targeting: A Practical Approach*, ed AL Joyner (Oxford University Press, Oxford), 2nd Ed., pp 1–35.
31. Kwan KM (2002) Conditional alleles in mice: Practical considerations for tissue-specific knockouts. *Genesis* 32:49–62.
32. Friedel RH, Wurst W, Wefers B, Kuhn R (2011) Generating conditional knockout mice. *Methods Mol Biol* 693:205–231.
33. Chen F, et al. (2011) High-frequency genome editing using ssDNA oligonucleotides with zinc-finger nucleases. *Nat Methods* 8:753–755.
34. Sander JD, et al. (2011) Targeted gene disruption in somatic zebrafish cells using engineered TALENs. *Nat Biotechnol* 29:697–698.
35. Tesson L, et al. (2011) Knockout rats generated by embryo microinjection of TALENs. *Nat Biotechnol* 29:695–696.
36. Klug A (2010) The discovery of zinc fingers and their applications in gene regulation and genome manipulation. *Annu Rev Biochem* 79:213–231.
37. Moore M, Choo Y, Klug A (2001) Design of polyzinc finger peptides with structured linkers. *Proc Natl Acad Sci USA* 98:1432–1436.
38. Moore M, Klug A, Choo Y (2001) Improved DNA binding specificity from polyzinc finger peptides by using strings of two-finger units. *Proc Natl Acad Sci USA* 98:1437–1441.
39. Team RDC (2011) *R: A Language and Environment for Statistical Computing* (R Foundation for Statistical Computing, Vienna, Austria).